STATE & NATIONAL: Today, chronic weight enthusiasts are quite likely rating Eli Lilly medications manufacturers A1 following the company's weight loss medication that has been approved by the food & Drug Administration. Eli Lilly is among the natuion's top drug producers and has established the trust of both the public and the FDA over the company's 147 years of providing for Americans. The company's Zepbound (tirzepatide) injection has been developed for those who are enthusiastic about weight loss. By Anne M. Erbynstein "Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes."--John Sharretts, M.D., Director; Division of Diabetes, Lipid Disorders, Obesity in the FDA’s Center for Drug Evaluation and Research. Following the apparent research that establsihed the approval of the Zepbound tirzepatide drug, also under the name Mounjaro, is already used to assist Type 2 diabetics with providing glucose (blood sugar) as a medication taken along with controlled diet and exercise. Dr John Sharetts commented in regard to the Zepbound drug found to be most efficient in the fight against obesity. Dr Sharretts stated that Zepbound is effective in responding to a great and increasing need by Americans who are members of an apparently growing community of obese people. Dr sharetts stated in reference to Zepbound, "...today’s approval addresses an unmet medical need.” Further stating the benefits that are provided by Zepbound, Dr Sharretts ' research indicates that more than 70% of americans are obese adding that obesity is responsible for weight related conditions including high blood pressure, diabetes and high cholesterol. Dr Sharretts states that, among Americans whose body mass registers at an "...index of 30 kilograms per square meter (kg/ m2) or greater or overweight an index of 27 kg/m2 or greater with at least one weight-related condition." Dr Sharrets stated, today, that obese adults who are actively working to lose 5 to 10 pounds are at a diminished risk of encountering a "...cardiovascular disease." Today, the FDA indicated that the sudy performed by Eli Lilly found that randomized groups receiving Zepbound while weighing as much as 231 pounds were among those who lost an average of 18% body weight compared to those included in the clinical trials who received placebos. The Eli Lilly study , also, found results among subject with Type 2 Diabetes. Among those who received the highest dosage of Zepbound and whose body weight averaged 222 pounds (101 kg) and average body mass index was 36 kg/m2, the sugjects in this category were benefitted by the loss of 12% of body weight. The FDA cautions chronic users of Zepbound stating that in addition to to evidence that the drug causes C-Cell thyroid tumors, the weight loss drug also causes side effects including "...nausea, diarrhea, vomiting, constipation, abdominal (stomach) discomfort and pain, injection site reactions, fatigue, hypersensitivity (allergic) reactions (typically fever and rash), burping, hair loss and gastroesophageal reflux disease." Zepbound should not be used by people who have a history of or have a congenital link to Type 2 Multiple Endocrine Neoplasia syndrome Endocrine condition. Zepbound causes tumors, including medullary thyroid cancer, in humans and ...should not be used in patients with a personal or family history of medullary thyroid cancer.
Comentarios